

RESEARCH

Open Access



Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets

Giulia Pecora^{1,2}, Camilla Mancini^{1,3}, Rossella Mazzilli¹, Virginia Zamponi^{1,2}, Stefano Telese⁴, Stefano Scalera⁵, Marcello Maugeri-Saccà⁵, Ludovica Ciuffreda⁶, Francesca De Nicola⁶, Maurizio Fanciulli⁶, Anna La Salvia⁷, Massimiliano Mancini⁸, Andrea Vecchione^{4,8}, Alessandra Siciliani⁹, Mohsen Ibrahim⁹, Diana Bellavia³, Andrea Marcello Isidori², Antongiulio Faggiano^{1*}, Rita Mancini^{4,8} and Claudia De Vitis⁴

Abstract

Background The molecular landscape of lung neuroendocrine neoplasms is still poorly characterized, making it difficult to develop a molecular classification and personalized therapeutic approaches. Significant clinical heterogeneity of these malignancies has been highlighted among poorly differentiated histotypes and within the subgroup of well-differentiated neuroendocrine tumors (NET). Currently, the main prognostic factors of lung NET include stage, histotype, grade, peripheral location, and demographic parameters. To gain deeper insights into the genomic underpinnings of lung NETs, we conducted a pilot investigation to uncover potential genetic mutations and copy number variations (CNVs) implicated in their pathogenesis.

Methods Formalin-fixed, paraffin-embedded intraoperative tumor biopsies and matched peripheral blood mononuclear cell samples were collected from six consecutive patients with lung NETs. The whole exome sequencing (WES) was performed to profile germline and somatic mutations, identify novel genetic alterations, and detect CNVs. Clinical and pathological data were systematically documented at diagnosis and during follow-up.

Results The WES analysis identified a subset of mutations shared between germline and somatic; some were of particular clinical interest as they were associated with tumor proliferation and potential therapeutic targets such as the genes *KDM5C*, *ATR*, *COL7A1*, *NOTCH4*, *PTPRS*, *SMO*, *SPEN*, *SPTA1*, *TAF1*. These mutations were predominantly linked to chromatin remodeling and were involved in critical oncogenic pathways such as Notch and Wnt signaling.

Conclusions This pilot study highlights the potential role of NGS analysis on solid biopsy in the assessment of the mutational profile of lung NET. A comparison of germline and somatic mutations is critical to identifying putative tumor driver mutations. In perspective, the enrichment of a subpopulation of cancer cells in the blood, with one or more specific mutations, is information of enormous clinical relevance, either for prognosis or therapeutic decisions. Translational studies on large prospective series are required to establish the role of liquid biopsy in lung NET.

Keywords Lung neuroendocrine tumors, Carcinoids, Next generation sequencing, Somatic mutation, Germline mutation, Whole exome sequencing, NET epigenetics, Notch pathway, Wnt pathway, Chromatin remodeling

*Correspondence:
Antongiulio Faggiano
antongiulio.faggiano@uniroma1.it
Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Background

Neuroendocrine Tumors (NET) are a miscellaneous group of malignancies originating from neuroendocrine cells distributed throughout the body and arising in various organs, including the gastrointestinal tract, lungs, pancreas, and thymus [1, 2]. For this reason are characterized by elevated heterogeneity, which makes difficult to achieve an uniform diagnostic definition and prognostic stratification. Lung NET are classified depending on morphology, mitotic count, necrosis, and cytological features. High-grade neuroendocrine carcinomas (NEC) include poorly differentiated histotypes. Low-grade NET includes the well-differentiated forms, the so-called typical (TC) and atypical carcinoids (AC) [3]. NET commonly overexpress somatostatin receptors (SSTR), which are becoming used as diagnostic and therapeutic targets [4]. Most carcinoids can be cured by surgery [5].

However, in the setting of advanced disease [6], somatostatin analogs (SSAs) are commonly used in non-rapidly progressive SST-positive L-NETs, although there is not a formal approval for this indication [7, 8], octreotide and lanreotide [9, 10], chemotherapy [11], and everolimus [12, 13], with variable tumor response. There are few validated molecular biomarkers in lung NET [14–17] and, therefore, no personalized strategies for clinical practice. However, in recent years, several works have highlighted the central role of genes involved in a few biological mechanisms such as chromatin remodeling, DNA repair and splicing [16–18]. This data alone makes urgent the need for accurate biomarkers for early diagnosis of NET patients, as well as their prognostic and therapeutic assessment to improve survival and clinical management [19, 20].

In this context we have conducted a pilot study on a cohort of six well differentiated lung NET, by high-throughput whole exome sequencing (WES) analysis, at germline and somatic level, to uncover any genetic mutation and copy number variations (CNVs) that might contribute to lung NET carcinogenesis. Our results could add new knowledge about the mutational landscape of NET to identify novel prognostic biomarkers and therapeutic targets that shall contribute to incorporating precision medicine in clinical practice and ameliorating lung NET outcomes.

Material and methods

Patients

Blood and tumor samples were obtained from 6 consecutive surgically treated lung NET patients collected at the AOU Sant'Andrea NET Unit. Inclusion criteria were a histologically confirmed diagnosis of lung NET (TC or

AC, according to 2021 World Health Organization classification). Patients with poorly differentiated neuroendocrine carcinomas (LCNEC and SCLC), high-grade NET G3, mixed neuroendocrine-epithelial histology, and non-neuroendocrine histology were excluded. Two patients were siblings, achieving the diagnosis of NET the same year. Expert NEN-dedicated pathologist (M. M) reviewed all histological samples in this study. For each patient, we collected formalin-fixed, paraffin-embedded (FFPE) tissue samples from the primary tumor and obtained corresponding blood samples at diagnosis (surgical or bioptical tissue sample). Clinical, biochemical and radiological data were collected at the diagnosis and during the follow-up. Written informed consent was obtained from all patients. This study was performed by the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Institutional Ethical Committee (n. 7269 protocol 0730/2023).

Clinical characteristics of the lung NET cohort

Patients with lung NET included were three women and three men, with an average age of 57.5 years (range 38–77). According to the pathological classification, five out of six lung NET were classified as TC, the remaining one was classified as AC. Tumor staging revealed that two patients had stage I NET, three had stage II NET, and one had stage III NET. The Ki-67 index was 0.5% in one patient, 1% in four patients, 3% in one patient. Mitotic counts ranged from 0.5 to 3.5 per 10 high-power fields. All patients with typical carcinoid were low grade NET G1, the patient with atypical carcinoid was intermediate grade NET G2. The mean diameter of the lesions was 3.5 cm, and all patients had positive immunostaining for neuroendocrine markers such as Cytokeratin AE1/AE3 (CK AE1/ AE3), Chromogranin A (CGA), Synaptophysin (SYN), and Insulinoma-associated protein 1 (INSM1). As regards regional nodal status, four patients had no regional lymph node involvement (N0), one patient had not evaluable regional nodal status (Nx) and one patient was N2. Tissue and blood samples were collected from all six patients before surgery. All enrolled patients displayed stable disease along the follow-up (7–17 months). The cohort's clinical characteristics and IHC neuroendocrine markers were summarized in Table 1.

PBMC and tissue sample processing

Peripheral blood mononuclear cells (PBMC) were isolated by a density gradient, using Lympholyte (Cedarlane), following the manufacturer's instructions [21]. The tumor tissue analysis was based on the FFPE samples. To minimize the generation of artefacts, in particular cytosine deamination, all samples used were

Table 1 Clinical pathological characteristics and IHC markers of lung NET cohort

ID	SANET_002	SANET_004	SANET_005	SANET_006	SANET_011	SANET_016
Sex	F	F	M	F	M	M
Age	77	43	66	64	38	57
Histotype	TC	TC	TC	TC	TC	AC
Localization	cr	cr	Cl	pr	cr	cl
Ki-67(%)	1	1	0.5	1	1	3
MI (mm ²)	1.5	1	1	0.5	0.5	3.5
Grade	G1	G1	G1	G1	G1	G2
Diameter (cm)	1.8	4.5	2.8	5	4.2	2.5
Stage	IA2	IIA	IIIB	IIB	IIA	IA3
CK AE1/AE3	+	+	+	+	+	+
CGA	+	+	+	+	+	−/+
SYN	+	+	+	+	+	+
INSM	+	+	+	+	+	+
TNM	pT1b pN0 LV10	pT2b pN0 LV10	pT4 pN2 LV11	pT3 pNx LV11	pT2b pN0 LV11	pT1c pN0 LV10
staging	PL0 R0	PL2 R1	PL2 R0	PL0 R0	PL0 R0	PL0 R0

TC = typical carcinoids; AC = atypical carcinoids; cr = central right; cl = central left; pr = peripheral right; MI = mitotic index; CK = Cytokeratin; CGA = Chromogranin A; SYN = Synaptophysin; INSM1 = Insulinoma-associated protein 1; TNM = Tumor–Nodes–Metastasis for IHC staining + = 100%; ± = 50–75%; −/+ = 25–50%; − = 0%

fixed at 4 °C. Afterwards the paraffin blocks were cut, and DNA was extracted using the GeneRead DNA FFPE Kit (Qiagen).

Bulk exome sequencing

DNA was extracted from PBMC and FFPE tissue using the DNeasy Blood & Tissue Kit (Qiagen) and GeneRead DNA FFPE Kit (Qiagen), respectively. Genomic DNA was quantified using the Qubit dsDNA BR Assay Kit (Invitrogen, Carlsbad, CA, USA). In contrast, DNA quality (DIN range from 1 to 10) was assessed using the 4200 TapeStation and the corresponding Genomic DNA ScreenTape assay (Agilent Technologies, CA, USA). 100 ng of genomic DNA was enzymatically fragmented using the SureSelect Enzymatic Fragmentation Kit (Agilent Technologies, CA). WES was carried out using the SureSelect XT HS2 DNA Reagent Kit for library preparation, and the coding regions were enriched using the all-exon probes V7 according to the manufacturer's instructions (Agilent Technologies, CA). The quality and quantity of the intermediate whole genome library was controlled on the 4200 TapeStation with the D1000 ScreenTape Analysis (Agilent Technologies, CA). After the exome enrichment, the quality of the final library was assessed using the 4200 TapeStation (High Sensitivity D1000 ScreenTape assay), and the quantity via RT-qPCR. The libraries were sequenced on an Illumina NovaSeq6000 platform (Illumina, San Diego, CA, USA) to generate 100 bp paired-end reads.

Bioinformatic analysis

Whole exome sequencing data was analyzed with Sarek version 3.1.1, a nf-core workflow designed to detect germline and somatic variants [22]. A comparison analysis was performed between germline and somatic, and then, for each patient, a head-to-head comparison was performed. Gene and variant annotations were performed with VEP (Variant Effect Predictor). Detection of oncogenic and clinically actionable mutations was performed with PCGR (Personal Cancer Genome Reporter) software [23]. Sites of mutation were chosen based on the following criteria: a minimum of 50 sequencing reads and minor allele frequency (MAF) ≥ 0.5. Oncoprint and Transition/Transversion plots and statistical tables on mutations were generated with Maftools R package [23]. The jaccard distance and hierarchical clustering were generated with the 'dendextend' library of R software v. 4.2. Gene ontology and pathway enrichment analyses were performed using ShinyGO, considering only terms with a false discovery rate (FDR) below 0.05. The protein–protein interaction network was constructed using STRINGdb.

Statistical analysis

Categorical data were summarized using frequencies and percentages and were compared using Fisher's exact test. Continuous variables were reported as median and were compared using the Mann–Whitney U test. A p-value < 0.05 was considered significant. Hierarchical clustering explored the relationship between PBMC and FFPE samples across patients. The Jaccard index distance

was employed to capture mutation similarity. Clustering results were compared to assess consistency and highlight systematic differences between sample types. The distance matrix was constructed based on the number of exonic mutations per sample.

Results

Comprehensive mutational profiling

To thoroughly characterize lung NET's genomic landscape, all samples underwent detailed mutational profiling. This included the assessment of CNVs, single nucleotide variant (SNV) classifications, mutation burden, and variant annotations through WES analysis. Notably, no significant focal CNVs were identified across the cohort. Our data highlighted a subversion of the type of mutation from germline to somatic. In particular, C>T transitions doubled from germline to somatic, becoming the most prevalent mutation in lung NET independently from patients (Fig. 1a, b). The total number of germline mutations was quintupled compared to the somatic (Fig. 1 and Table 2). In detail, we revealed 11.889 germline mutations and 2.248 somatic mutations, with an average number of variants/sample of 1981.5 and 374.6, respectively. Notably, the patient with the most advanced tumor stage shows a more significant number of somatic mutations with p -value=0.05 (Fig. 1). Concerning the tumor mutational burden (TMB), carcinoids showed low TMB (0.18–2.79 mut/Mb), confirming existing data in the literature [15, 24] (Table 2). Different types of genomic alterations were found, such as missense variants, stop gained, stop lost, frameshift variants, inframe deletions, inframe insertion, splice variants, multihit, and others (Fig. 1). Germline and somatic mutations were mainly determined by single nucleotide variants (SNVs), such as frameshift deletions (44% vs. 35%) and missense mutations (31% vs. 24%), respectively. Furthermore, mutations affecting splicing sites increased from germline to somatic (5% vs. 14%) (Table 2). In summary, our analysis revealed a notable shift in the mutation profile from germline to somatic, characterized by an increased prevalence of mutations at splicing sites. Additionally, we found a correlation between TMB and the stage of the disease.

Key genetic mutations and epigenetic alterations

Germline and somatic genes mutations identified in the study cohort are summarized in Fig. 2. Among the most frequent mutations, we found 50 genes known to be related to carcinogenesis. The genes displayed in the Oncoprint (Fig. 2) were selected from the lung NET cohort included in The AACR Project GENIE Consortium, using their online platform [25–27]. The recurrence rate of somatic mutations in this study is lower than that

found in gastroenteropancreatic NET (GEP-NET), confirming the greater clinical and molecular heterogeneity of the former compared to the latter [28]. Lysine (K)-specific demethylase 5C (*KDM5C*) was mutated in 50% of cases. In contrast, another subset of genes such as Ataxia telangiectasia and Rad3-related (*ATR*), Collagen Type VII Alpha 1 Chain (*COL7A1*), Notch Receptor 4 (*NOTCH4*), Receptor-type tyrosine-protein phosphatase S (*PTPRS*), Smoothened (*SMO*), Spen Family Transcriptional Repressor (*SPEN*), Spectrin Alpha, Erythrocytic 1 (*SPTA1*) and TATA-box binding protein-associated factor 1 (*TAF1*) was mutated in 33% of cases. Other genes were mutated in 17% of cases. Interestingly, all the samples analyzed had at least one gene mutation involved in chromatin remodeling. These genes encoded covalent histone modifiers and subunits of the SWI–SNF complexes such as *KDM5C*, AT-rich interaction domain 1A (*ARID1A*), *PTPRS*, *TAF1*, Axis inhibition protein 2 (*AXIN2*), Spen Family Transcriptional Repressor (*SPEN*), Lysine Methyltransferase 2A (*KMT2A*), Lysine Methyltransferase 2B (*KMT2B*) and DNA methyltransferase 3 beta (*DNMT3B*). Interestingly, patients sharing somatic mutations in the *KDM5C* (c.2623-51_2729del), *NOTCH4* (c.1625-86_1729del), *SMO* (c.1779_1801+83del), *TAF1* (c.4315_444+96del) genes carried the same specific mutations (see Additional file 1). Furthermore, consistent with data shown in Fig. 1b, the patient with the highest number of somatic mutations and the most advanced stage of the disease also had the most mutated genes. Regarding the prognostic and predictive mutation potential, all mutations were classified as TIER 3 or TIER 4 (data not shown), according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) [29]. Germline genes such as *FAT1* (100%), *BRCA2* (83%), *LRP1B* (83%), *NSD1* (83%), *APC* (67%), *ARID1A* (67%), *COL7A1* (67%), *PRKDC* (67%) and *ZFHX3* (67%) were consistently mutated. Overall, the oncogenic mutations shared between germline and somatic involved *ARID1A*, *COL7A1*, *SPTA1*, *FAT1*, *APC*, *CUX1*, *BCR*, *KMT2A*, *KMT2B*, *KMT2D*, *BCOR*, *IGF2R*, *MED12* and *ERBB4* genes (see Additional file 2). In addition, other highly shared somatic mutations affected genes *REG3A* (100%), *FMNL1* (83%), *TCF15* (83%), *CC2D2A* (67%), *KRTAP9-9* (67%), *SOHLH1* (67%), *TLE4* (67%) (see Additional file 3). In summary, lung NET showed a marked molecular heterogeneity with the *KDM5C* gene somatically mutated in half of the patients. In contrast, *ATR*, *COL7A1*, *NOTCH4*, *PTPRS*, *SMO*, *SPEN*, *SPTA1*, and *TAF1* genes were mutated in a third of cases. Notably, all the samples analyzed had at least one gene mutation involved in epigenetic mechanisms.




Fig. 1 Mutational profiling of samples derived from PBMC and FFPE. **a** PBMC-derived samples. The upper panel shows the transitions (Ti) and transversions (Tv) ratio, along with the distribution of single nucleotide variants (SNVs) for each sample. The lower panel displays the total number of mutations identified, categorized by variant classification, for each patient. **b** FFPE-derived samples. The upper panel shows the Ti/Tv ratio and SNV distribution for each sample. The lower panel displays the total number of mutations identified, categorized by variant classification, for each patient. FFPE-derived samples show a significantly higher number of mutations compared to PBMC-derived samples, with a predominance of variants classified as Missense Mutation and Frame Shift Del

Hierarchical clustering dendrogram

We performed hierarchical clustering analysis using exonic non-silent genetic mutations from each sample (Fig. 3). The cluster dendrogram supported genetic similarity, in terms of their mutational profile, between FFPE SA-002 and FFPE SA-011 samples and between

FFPE SA-005 and FFPE SA-006 samples. The genetic similarity between the SA-005 and SA-006 samples and germinal and somatic samples was justified because the two patients were siblings. Interestingly, despite the genetic similarity, the two siblings showed different clinical pathological features (Table 1). Furthermore,

Table 2 Number and type of germline and somatic mutations and TMB for each patient

ID	Deletion		Insertion	MSS	NSS	NST	Splice Site	Translation Start Site	TMB (mut/Mb)	Total
	Frame Shift	In Frame	In Frame							
SA-NET-002-PBMC	1156	213	248	717	53	7	128	1		2523
SA-NET-002-FFPE	142	44	26	81	41	1	42	4	0.44	381
SA-NET-004-PBMC	169	42	25	190	8	1	3	0		438
SA-NET-004-FFPE	116	24	18	98	34	5	98	4	1.53	397
SA-NET-005-PBMC	1118	207	214	714	47	5	104	3		2412
SA-NET-005-FFPE	236	110	26	119	105	3	30	2	2.79	631
SA-NET-006-PBMC	1082	209	215	679	36	4	98	2		2325
SA-NET-006-FFPE	111	28	13	74	11	2	101	2	0.68	342
SA-NET-011-PBMC	940	160	163	589	48	9	57	3		1969
SA-NET-011-FFPE	88	20	18	91	20	2	27	0	0.35	266
SA-NET-016-PBMC	760	176	164	846	36	10	227	3		2222
SA-NET-016-FFPE	89	13	13	83	19	1	12	1	0.18	231

Missense (MSS), Nonsense (NSS), Nonstop (NST), Tumor Mutational Burden (TMB)

patient 004 demonstrated a high degree of genetic overlap between germline and somatic components.

Pathway enrichment reveals critical roles of Notch and Wnt signaling

Afterward, we conducted a Gene Ontology (GO), such as Pathway enrichment analysis, to understand whether the mutated genes were part of any significant signaling pathway for lung NET, by Biological Process Enrichment and Elsevier Pathway Collection. Our analyses uncovered that six genes (*KDM5C*, *NOTCH4*, *TAF1*, *ARID1A*, *SPEN*, *FAT1*) were involved in the “*NOTCH signaling pathway*” and “*Positive regulation of transcription of NOTCH receptor target*” in the GO Biological Process Enrichment (Fig. 4a and Additional file 4). Furthermore, two genes (*SPEN*, *NOTCH4*) were also involved in the “*NOTCH receptor signaling*” in the GO Elsevier Pathway Collection (Fig. 4b and Additional file 5). Three genes (*AXIN2*, *APC*, *SMO*) were involved in the “*Activation of the Wnt pathway by blocking tumor suppressor genes*” and in “*Wnt canonical signaling activation in cancer*” in the Elsevier Pathway Collection (Fig. 4b). In conclusion, we highlighted that most mutated genes had a role in chromatin remodeling mechanism, contributing to shared functions that mainly involved the Notch and Wnt pathways (Fig. 4c).

Discussion

WHO classification defines clinically relevant subgroups of lung NET, but there is still a need for better diagnostic definition and prognostic stratification within histological subtypes. Lung NET are malignant tumors with variable clinical aggressiveness only in part predictable. The most

relevant prognostic factors include age, gender, performance status, peripheral location, tumor stage, and histotype [1]. In particular, the well-differentiated forms TC and AC show low proliferative activity but increased from TC to AC [7]. Unfortunately, to date, only a few biomarkers have been established as clinically useful and reliable tools for the prediction of prognosis or response to treatment [14]. The considerable heterogeneity in their clinical presentation and histological and biological features could improve their clinical management and prompt diagnosis [20]. NET commonly overexpress somatostatin receptors (SSTR), which are becoming used as diagnostic and therapeutic targets [4]. The gold standard of care for early-stage patients is surgery [5]. However, a variable range of postoperative recurrence has been reported [6, 30]. Metastatic diseases at first diagnosis range from 20 to 70%, which hinders complete tumor debulking [31]. In the setting of advanced disease, few options are available. SSAs are commonly used in non-rapidly progressive SST-positive L-NETs, although there is not a formal approval for this indication [7, 8], octreotide and lanreotide [9, 10], chemotherapy [11], and everolimus [12, 13], with variable tumor response. In addition, a promising therapeutic option for the future is peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE (a somatostatin analog linked to a radioisotope that mainly targets SSTR2 and SSTR5). PRRT, indeed, has shown a certain degree of efficacy in controlling the progression of disease also in lung NET [32]. Tumor relapse in surgically treated disease and tumor progression in the advanced disease under systemic therapy are for the most unpredictable, required validation of reliable prognostic and predictive markers.




Fig. 2 Oncoprint representation of mutational frequencies in genes across PBMC and FFPE samples. **a** PBMC-derived samples. The Oncoprint shows the mutation frequency of selected genes across all samples ($n=6$), with mutation counts represented in the top bar plot. The heatmap displays the percentage of mutations identified per gene for each sample, categorized by variant classification (e.g., Missense Mutation, Frame Shift Del, Nonsense Mutation, etc.). **b** FFPE-derived samples. The Oncoprint illustrates the mutation frequency of the same genes across FFPE samples ($n=6$). The mutation counts are represented in the top bar plot, while the heatmap shows the percentage of mutations for each gene, categorized similarly to the PBMC samples

Nowadays, there are no validated molecular biomarkers in lung NET and no personalized strategies or clinical practice. In this context, the NETest, a NET-specific liquid biopsy, evaluates the expression of 51 NET genes by RT-qPCR. Its diagnostic utility has been widely demonstrated, while its prognostic and predictive role is still debated [33]. To date, the most comprehensive and robust genomic analysis by whole-genome sequencing was conducted in pancreatic NET (PanNET) [34].

On the other hand, lung NET's genetic profile could represent a valid tool for better characterizing tumor behavior and outcomes, and recent improvements in Next-Generation Sequencing (NGS) technologies have

enhanced the exploration of lung NET's genetic background. Many efforts have been made and are ongoing to decipher the molecular landscape of lung NET, such as the lungNENomics project and the Rare Cancers Genomics initiative [35]. Lung NET rarely harbors driver mutations commonly found in non-small cell lung cancer or *TP53/RB1* mutations found universally in small cell lung cancer (SCLC) [14, 36]. A genome/exome sequencing analysis, collecting specimens from different biobanks, mostly TC, has reported that chromatin-remodeling is the most frequently altered molecular pathway in lung NET [16]. In this regard, some critical studies have highlighted some recurrent mutations that




Fig. 3 Clustering of PBMC and FFPE samples based on Jaccard Index. Hierarchical clustering dendrogram showing the similarity between PBMC and FFPE samples based on their mutational profiles, as measured by the Jaccard Index. The clustering reveals distinct separation between PBMC-derived and FFPE-derived samples, suggesting systematic differences in the mutational landscape captured by the two sample types

mainly affect the genes that regulate chromatin remodeling, such as *MEN1*, *ARID1A*, *KMT2D*, *KTMD2C*, *NOTCH2*, *EIF1AX*, *TERT1*, and *PCLO* [14–16]. In addition, the dysregulation of the splicing machinery in lung NET has been demonstrated, suggesting the therapeutic druggability of *NOVA1*, *PRPF8*, and *SRSF10* [18]. Nevertheless, the mutations across samples were often non-overlapping, posing potential difficulty for the design of targeted therapeutic strategies. Furthermore, no recurrent genomic alterations were found in the PI3K/AKT/mTOR pathway [16], reported only in 2% of these tumors in another study [17]. A low expression of the pro-apoptotic tumor suppressor gene *CD44* and the transcription

factor *OTP* expression were indicators of poor outcomes in lung NET [37]. Moreover, other studies demonstrated that the *OTP* expression was associated with the prognosis [38] and most likely due to changes in DNA methylation levels [39].

The results of another study demonstrated that high *TERT* expression defines clinically aggressive lung NET with fatal outcomes, similar to neuroblastoma [40]. Leunissen’s work enabled the identification of molecular-defined lung NET subgroups (A1, A2, B), using an IHC marker panel (*OTP*, *ASCL1*, and *HNF1A*) [41].

Our study was performed to identify potential therapeutic targets within lung NET, similar to how everolimus

(See figure on next page.)

Fig. 4 Enrichment analysis and network visualization of mutated genes. **a** Biological process enrichment analysis of mutated genes. The bar plot displays the significantly enriched biological processes based on gene ontology (GO) terms, ranked by fold enrichment. The size of the dots represents the number of genes involved, while the color indicates statistical significance ($-\log_{10}(\text{FDR})$). Notch signaling pathway appears prominently enriched. **b** Pathway enrichment analysis using the Elsevier Pathway Collection. The plot shows the significantly enriched pathways among the mutated genes, with the most relevant pathways being related to WNT signaling activation, NOTCH receptor signaling, and DNA damage checkpoint regulation. The size of the dots indicates the number of genes involved, and the color scale represents the significance level. **c** Protein–protein interaction network of mutated genes. The network highlights interactions between genes, with nodes related to Notch signaling shown in green and nodes related to WNT signaling shown in red. The network suggests potential cross-talk between these pathways, which may contribute to tumor progression and resistance to therapy




Fig. 4 (See legend on previous page.)

targets the mTOR pathway [42]. We directly compared germline and somatic genetic alterations on a cohort of 6 lung NET, which is scarcely described to date conducted by WES analysis. As for the total number of mutations in the germline it was five times more than in the somatic and C>T transitions were double in the somatic compared to the germline, in which mostly transversions were detected. As observed in our data (11.889 germline vs. 2.248 somatic mutations), this disproportion may reflect several factors, including the intrinsic biological stability of well- differentiated lung NETs, which tend to have a low somatic mutation burden. This observation is consistent with previously published studies [16, 18], reporting low tumor mutational burden and highlighting chromatin remodeling genes as major contributor in lung carcinoids. In addition, our results highlighted a correlation between disease progression and genomic instability. Gagliardi's recent study also highlighted the highest percentage of variants found consisting of a C>T transition [28].

Furthermore, the increased mutation rate in the splicing site, at somatic level, corroborates the results of the Blázquez-Encinas, which demonstrated the alteration of splicing machinery in lung carcinoids, also by in vitro functional studies [18]. However, we identified some common somatic mutations, involving *KDM5C*, *ATR*, *COL7A1*, *NOTCH4*, *PTPRS*, *SMO*, *SPEN*, *SPTA1*, *TAF1* genes, that had only been partially described in lung NET.

The comparison of germline and somatic mutations, critical to identifying putative tumor driver mutations, identified four specific recurrent mutations that were present at both germline and somatic levels which included genes as *KDM5C*, *NOTCH4*, *SMO* and *TAF1*.

Furthermore, as already argued by F. Cuesta and coworkers, our data also suggest that inactivation of chromatin-remodelling genes is sufficient to drive transformation in lung NET [16]. Infact, we detected mutations in chromatin remodeling genes in all the samples analyzed. These genes encoded covalent histone modifiers and subunits of the SWI–SNF complex such as *KDM5C*, *ARID1A*, *PTPRS*, *TAF1*, *AXIN2*, *SPEN*, *KMT2A*, *KMT2B* and *DNMT3B*; confirming that chromatin modifiers are fundamental players in the pathogenesis of lung NET [16].

The genetic cluster dendrogram highlighted genetic similarity between the SA-005 and SA-006 samples that were siblings. Interestingly, despite the genetic similarity, they showed different clinical pathological features (Table 1). This concept is probably related to the fact that somatic oncogenic mutations differed in the number and type of involved genes. This aspect is a valuable starting point for future investigations. Furthermore, patient 004 demonstrated a high degree of genetic overlap between

germline and somatic components, raising the possibility of an underlying hereditary predisposition.

Furthermore, the pathway enrichment analysis highlighted that mostly genes are involved in Notch signaling (*KDM5C*, *NOTCH4*, *TAF1*, *ARID1A*, *SPEN*, *FAT1*) and in the activation of the Wnt pathway (*AXIN2*, *APC*, *SMO*).

The histone demethylase *KDM5C* alterations were common in various cancers, regulating cancer cell proliferation invasion, drug resistance [43]. Abnormality of *NOTCH4* expression affects several tumor-cell behaviors, including stemness, the epithelial–mesenchymal transition (EMT), radio/chemoresistance, and angiogenesis [44]. *TAF1* aberrant activity has been implicated in cancer progression through its involvement in chromatin remodeling, its interaction with the androgen receptor [45] and the inactivation of tumor suppressor mechanisms, such as p53 [46]. The *ARID1A* protein is known to comprise the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complexes1. Gene alterations, leading to loss of function of *ARID1A*, occur in ~6% of cancers [47]. *SPEN* has been suggested to play a role in gene regulation in cell signaling, including the Notch signaling pathways. It has been also identified as a major regulator of the X Chromatin inactivation (XCI) in mammals and its alterations have been identified in several cancers [48]. In numerous cancers, disruption in *FAT1* activity facilitates EMT and contributes to cancer initiation/stem-like cell development [49]. *APC* is primarily recognized for its role as a negative regulator of the Wnt/b-catenin pathway and it is frequently mutated in colorectal and other epithelial cancers especially in the early stages of cancer development, establishing *APC* as a critical gatekeeper of tumor progression and a promising therapeutic target [50]. *AXIN2* is a key regulator of the Wnt/b- catenin signaling pathway, influencing cell proliferation, migration, and apoptosis, and acting as a tumor suppressor gene and epigenetic regulator in tumorigenesis [51]. *SMO* gene, essential in the Hedgehog (Hh) signaling pathway, is mutated in basal cell carcinoma and medulloblastoma [52]. It has a role in tumor cell growth, differentiation and migration, as well as therapeutic resistance [53, 54]. These results confirm current knowledge but further emphasize a small set of cellular pathways in lung NET, defining these as the key pathways in this tumor type [41, 51, 55, 56]. The fact that most mutated genes participate in shared functions, mainly involving Notch and Wnt signaling, could be explained by their potential interaction, already known in other types of tumor, through various mechanisms such as that orchestrated by *Jagged 1* [57, 58]. So, our findings highlighted the Notch and Wnt signaling pathways as promising areas for therapeutic intervention. Notch signaling is a critical pathway involved in lung cancer progression,

dysregulation of NOTCH receptors, such as NOTCH4, affects tumor-cell behaviors, including stemness and chemoresistance [59]. Targeting Notch signaling represents a promising therapeutic strategy. Various approaches, including the use of γ -secretase inhibitors, have been explored to modulate NOTCH activity in other cancer treatments [60]. The Wnt/b-catenin signaling pathway is known to play a significant role in various cancers, including lung cancer. Inhibitors targeting this pathway have demonstrated antitumor properties. For instance, the PORCN inhibitor WNT974 has shown efficacy in NET cell lines by inhibiting Wnt signaling, leading to reduced tumor cell viability. Similarly, the b-catenin inhibitor PRI-724 has exhibited growth-inhibitory effects in NET cells [61]. Therefore, these studies should be extended to a larger population to uncover potential molecular targets that could lead to the development of targeted therapies even for lung NET.

The major limitation of our study is represented by the low sample size and by the intrinsic heterogeneity of these tumors. In fact, among patients there was a lower percentage of shared comparing to our previous work on GEP-NET [28]. On the other hand, the strengths are the in-depth genomic analysis and the correlation with the patients' clinicopathological data.

Conclusions

This research on a hand confirms previous knowledge but on the other hand focuses attention on unknown genes mutations involved in two essential signaling pathways, such as Notch and Wnt, only partially investigated in lung NET. Nevertheless, NGS data, even if highly informative, need to be validated with transcriptomics and proteomics data and within vivo/in vitro functional studies. In prospective, if confirmed, the enrichment of a subpopulation of cancer cells in the blood, with one or more specific mutations, will be an information of enormous clinical significance because this would allow the progress of the disease to be monitored with an alternative less invasive procedure as ctDNA sequencing from liquid biopsy. The next objective will therefore be to compare the tissue mutational profile from solid biopsy with that resulting from liquid biopsy in lung NET.

Abbreviations

NET	Neuroendocrine tumors
CNVs	Copy number variations
FFPE	Formalin-fixed Paraffin-embedded
PBMC	Peripheral blood mononuclear cells
TC	Typical carcinoid
AC	Atypical carcinoid
NEC	Neuroendocrine carcinomas
SSTR	Somatostatin receptor
GEP	Gastroenteropancreatic
LCNEC	Large cell neuroendocrine carcinoma
SCLC	Small cell lung cancer

NEN	Neuroendocrine neoplasm
CK	Cytokeratin
CGA	Chromogranin A
SYN	Synaptophysin
INSM1	Insulinoma-associated protein 1
RT-qPCR	Real-time quantitative PCR
NGS	Next generation sequencing
WES	Whole exome sequencing
VEP	Variant effect predictor
PCGR	Personal cancer genome reporter
MAF	Minor allele frequency
SNV	Single nucleotide variants
Ts	Transitions
Tv	Transversion
TMB	Tumor mutational burden
MSS	Missense
NSS	Nonsense
NST	Nonstop
ESCAT	ESMO Scale for Clinical Actionability of Molecular Targets
AACR	American association for cancer research
XCI	X Chromatin inactivation
GO	Gene ontology
PanNET	Pancreatic NET
EMT	Epithelial–Mesenchymal transition
WHO	World Health Organization
SSAs	Somatostatin analogs
PRRT	Peptide receptor radionuclide therapy
ctDNA	Circulating tumoral DNA

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12967-025-06442-1>.

Additional file 1. Somatic mutation dataset.

Additional file 2. Germline and somatic common mutations. Mutated samples per oncogenic mutation shared between germline and somatic.

Additional file 3. Top fifty somatic mutations panel. The fifty most frequent somatic mutations.

Additional file 4. Biological process enrichment analysis data. Biological process enrichment analysis raw data.

Additional file 5. Elsevier Pathway Collection analysis data. Elsevier Pathway Collection enrichment analysis raw data.

Acknowledgements

Not applicable.

Author contributions

AF, AMI, CDV, MF, RM: conceptualization and design; CDV, GP, SS: methodology; AS, CM, FDN, GP, LC, MM, RM, SS, ST, VZ: investigation; ALS, CDV, RM, VZ: formal analysis; CDV, CM, GP: writing—original draft preparation; AF, ALS, CDV, DB: writing—review and editing; AF, AMI, AV, CDV, MF, MI, MMS, RM: supervision. All authors read and approved the final manuscript.

Funding

The research leading to these results has received funding from the European Union—NextGenerationEU through the Italian Ministry of University and Research under PNRR—M4C2- I1.3 Project PE_00000019 “HEAL ITALIA” to Antongiulio Faggiano and Andrea M. Isidori CUP B53C22004000006. This work was supported by the Italian Association for Cancer Research (AIRC) grants IG24451 to Rita Mancini, and by Fondo di Ricerca di Ateneo 2022 to Claudia De Vitis (RM12218167B3A0D3).

Availability of data and materials

The datasets supporting the conclusions of this article will be available on the European Genome-phenome Archive (EGA), <https://ega-archive.org>. In addition, all data from this study can be obtained from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Written informed consent was obtained from all patients. This study was performed by the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Institutional Ethical Committee (n. 7269 protocol 0730/2023). All human samples, encompassing sequencing samples and IHC staining specimens, were performed on existing samples collected during standard diagnostic tests, posing no extra burden to patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Unit of Endocrinology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU Sant'Andrea, ENETS Center of Excellence, Rome, Italy. ²Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. ³Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. ⁴Department of Clinical and Molecular Medicine, Sant'Andrea Hospital-Sapienza University of Rome, Rome, Italy. ⁵Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ⁶UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, Translational Research Area, IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy. ⁷National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy. ⁸Morphologic and Molecular Pathology Unit, S. Andrea University Hospital, Rome, Italy. ⁹Department of Thoracic Surgery, Sant'Andrea University Hospital, Rome, Italy.

Received: 4 February 2025 Accepted: 28 March 2025

Published online: 14 May 2025

References

- Vocino Trucco G, Righi L, Volante M, Papotti M. Updates on lung neuroendocrine neoplasm classification. *Histopathology*. 2024;84:67.
- Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers. Vol. 31, *Journal of Endocrinological Investigation*. 2008.
- 2022 WHO classification of Thoracic Tumors (5th Ed.), IARC Press, Lyon.
- Popa O, Taban S, Pantea S, Ploeanu A, Barna R, Cornianu M, et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. *Exp Ther Med*. 2021;22(4).
- Davini F, et al. *J Cardiovasc Surg*. 2009;50(6):807–11.
- Annals of Oncology* (2021) 32 (suppl_5):S906–S920. <https://doi.org/10.1016/annonc/annonc678>.
- Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol*. 2015;26(8):1604–20.
- Faggiano A. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. *J Endocrinol Invest*. 2023;47(1):35–46.
- Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*. 2009;27(28):4656–63.
- Baudin E, Capdevila J, Hörsch D, Singh S, Caplin ME, Wolin EM, et al. Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. *Endocr Relat Cancer*. 2024;31(9).
- Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT -4 lung subgroup analysis. *Cancer Sci*. 2018;109(1):174–81.
- Ferolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Marconcini R, et al. Efficacy and safety of lanreotide autogel and temozolomide combination therapy in progressive thoracic neuroendocrine tumors (carcinoid): results from the phase 2 ATLANT study. *Neuroendocrinology*. 2023;113(3):332–42.
- Faggiano A, Malandrino P, Modica R, Agrimi D, Aversano M, Bassi V, et al. Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature. *Oncologist*. 2016;21(7):875–86.
- Sun TY, Hendifar A, Padda SK. Lung neuroendocrine tumors: how does molecular profiling help? *Curr Oncol Rep*. 2022;24(7):819–24.
- Sen T, Dotsu Y, Corbett V, Puri S, Sen U, Boyle TA, et al. Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. *Lancet Oncol*. 2025;26(1):e13–33.
- Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidel D, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nat Commun*. 2014;5(1):3518.
- Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. *J Pathol*. 2017;241(4):488–500.
- Blázquez-Encinas R, García-Vioque V, Caro-Cuenca T, Moreno-Montilla MT, Mangili F, Alors- Pérez E, et al. Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery. *J Transl Med*. 2023;21(1):879.
- Mathian É, Drouet Y, Sexton-Oates A, Papotti MG, Pelosi G, Vignaud JM, et al. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. *ESMO Open*. 2024;9(6): 103591.
- Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, et al. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence: Survey from the ENETS lung NET task force. *J Neuroendocrinol*. 2024;36(8).
- Sacconi A, De Vitis C, de Latouliere L, di Martino S, De Nicola F, Goeman F, et al. Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. *Cell Death Dis*. 2021;12(11):1019.
- Ewels PA, Peltzer A, Fillingier S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol*. 2020;38(3):276–8.
- Nakken S, Fournous G, Vodák D, Aasheim LB, Myklebost O, Hovig E. Personal Cancer Genome Reporter: variant interpretation report for precision oncology. *Bioinformatics*. 2018;34(10):1778–80.
- Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med*. 2017;9(1):34.
- AACR Project GENIE: https://genie.cbioportal.org/study/summary?id=genie_public.
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6(269).
- de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazon T, et al. Analysis and Visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. *Cancer Res*. 2023;83(23):3861–7.
- Gagliardi I, Campolo F, Borges de Souza P, Rossi L, Albertelli M, Grillo F, et al. Comparative targeted genome profiling between solid and liquid biopsies in gastroenteropancreatic neuroendocrine neoplasms: a proof-of-concept pilot study. *Neuroendocrinology*. 2024;1–12.
- Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol*. 2018;29(9):1895–902.
- Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, et al. Natural history of localized and locally advanced atypical lung carcinoids

- after complete resection: a joined French-Italian retrospective multi-center study. *Neuroendocrinology*. 2018;106(3):264–73.
31. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol*. 2017;3(10):1335.
 32. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. *CA Cancer J Clin*. 2018;68(6):471–87.
 33. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*. 2017;543(7643):65–71.
 34. Speisky D, Duces A, Bièche I, Rebours V, Hammel P, Sauvanet A, et al. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. *Clin Cancer Res*. 2012;18(10):2838–49.
 35. Computational Cancer Genomics: <https://rarecancersgenomics.com>.
 36. Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, et al. Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations. *J Thorac Oncol*. 2019;14(9):1651–61.
 37. Swartz DRA, Henfling MER, Van Neste L, van Suylen RJ, Dingemans AMC, Dinjens WNM, et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. *Clin Cancer Res*. 2013;19(8):2197–207.
 38. Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Prinzi N, et al. Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids. *Histopathology*. 2023;82(6):870–84.
 39. Moonen L, Mangiante L, Leunissen DJG, Lap LMV, Gabriel A, Hillen LM, et al. Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation. *Int J Cancer*. 2022;150(12):1987–97.
 40. Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegelé C, Sexton-Oates A, et al. TERT expression and clinical outcome in pulmonary carcinoids. *J Clin Oncol*. 2025;43(2):214–25.
 41. Leunissen DJG, Moonen L, von der Thüsen JH, den Bakker MA, Hillen LM, van Weert TJJ, et al. Identification of defined molecular subgroups on the basis of immunohistochemical analyses and potential therapeutic vulnerabilities of pulmonary carcinoids. *J Thoracic Oncol*. 2024;20:451.
 42. Falkowski S, Woillard JB. Therapeutic drug monitoring of everolimus in oncology: evidences and perspectives. *Ther Drug Monit*. 2019;41(5):568–74.
 43. Chen XJ, Ren AQ, Zheng L, Zheng ED. Predictive value of KDM5C alterations for immune checkpoint inhibitors treatment outcomes in patients with cancer. *Front Immunol*. 2021;19:12.
 44. Xiu M, Zeng X, Shan R, Wen W, Li J, Wan R. Targeting Notch4 in cancer: molecular mechanisms and therapeutic perspectives. *Cancer Manag Res*. 2021;13:7033–45.
 45. Tavassoli P, Wafa LA, Cheng H, Zoubeydi A, Fazli L, Gleave M, et al. TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. *Mol Endocrinol*. 2010;24(4):696–708.
 46. Wen J, Wang D. Deciphering the PTM codes of the tumor suppressor p53. *J Mol Cell Biol*. 2022;13(11):774–85.
 47. Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. *Cancer Treat Rev*. 2021;100: 102287.
 48. Kaufmann C, Wutz A. IndiSPENSable for X chromosome inactivation and gene silencing. *Epigenomes*. 2023;7(4):28.
 49. Chen ZG, Saba NF, Teng Y. The diverse functions of FAT1 in cancer progression: good, bad, or ugly? *J Exp C Clin Cancer Res*. 2022;41(1):248.
 50. Lesko A, Goss K, Prosperi J. Exploiting APC function as a novel cancer therapy. *Curr Drug Targets*. 2014;15(1):90–102.
 51. Li S, Wang C, Liu X, Hua S, Liu X. The roles of AXIN2 in tumorigenesis and epigenetic regulation. *Fam Cancer*. 2015;14(2):325–31.
 52. Wang J, Cheng H, Zhao X, Zhang X, Ding X, Huang T. Imperatorin suppresses aberrant hedgehog pathway and overcomes smoothened antagonist resistance via STAT3 inhibition. *Drug Des Devel Ther*. 2024;18:5307–22.
 53. Ji W, Niu X, Yu Y, Li Z, Gu L, Lu S. SMO mutation predicts the effect of immune checkpoint inhibitor: from NSCLC to multiple cancers. *Front Immunol*. 2022;3:13.
 54. Lou H, Li H, Huehn AR, Tarasova NI, Saleh B, Anderson SK, et al. Genetic and epigenetic regulation of the smoothened gene (SMO) in cancer cells. *Cancers (Basel)*. 2020;12(8):2219.
 55. Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, et al. Deregulation of Wnt/ β -catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. *Carcinogenesis*. 2013;34(5):953–61.
 56. Karwacki-Neisius V, Jang A, Cukuroglu E, Tai A, Jiao A, Predes D, et al. WNT signalling control by KDM5C during development affects cognition. *Nature*. 2024;627(8004):594–603.
 57. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno À, Fernández-Majada V, Grilli A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. *Proc Natl Acad Sci*. 2009;106(15):6315–20.
 58. Pelullo M, Zema S, Nardoza F, Checquolo S, Screpanti I, Bellavia D. Wnt, Notch, and TGF- β pathways impinge on hedgehog signaling complexity: an open window on cancer. *Front Genet*. 2019;21:10.
 59. Ahn HM, Park SY, Choi Y, Kim J, Lee Y. Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer. *Drug Resist Updates*. 2025;79: 101198.
 60. Galluzzo P, Bocchetta M. Notch signaling in lung cancer. *Expert Rev Anticancer Ther*. 2011;11(4):533–40.
 61. Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Inhibition of Wnt/ β -catenin signaling in neuroendocrine tumors in vitro: antitumoral effects. *Cancers (Basel)*. 2020;12(2):345.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com